Eric Van Cutsem

36PUBLICATIONS
249CO-AUTHORS
Molecular targetsChemotherapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Apr 21, 2026
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

|Apr 16, 2026
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings.

|Dec 30, 2025
CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma.

Luigi Brancato, Damar Osok, Laurent Van den Bossche

|Nov 14, 2025
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Mohamed E Salem, Alberto Puccini, Elizabeth Mauer

|Nov 04, 2025
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.

Pascal Hammel, Jean-Philippe Metges, Teresa Macarulla Mercade

|May 31, 2025
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.

Kohei Shitara, Sylvie Lorenzen, Jin Li

Pageof 6

Frequent Collaborators

12 joint publications

Josep Tabernero

6 joint publications

Thierry André

6 joint publications

Takayuki Yoshino

4 joint publications

Aimery deGramont